318 related articles for article (PubMed ID: 20524776)
1. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
[TBL] [Abstract][Full Text] [Related]
2. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.
Almasi CE; Høyer-Hansen G; Christensen IJ; Pappot H
APMIS; 2009 Oct; 117(10):755-61. PubMed ID: 19775344
[TBL] [Abstract][Full Text] [Related]
5. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
[TBL] [Abstract][Full Text] [Related]
6. The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
Almasi CE; Drivsholm L; Pappot H; Høyer-Hansen G; Christensen IJ
APMIS; 2013 Mar; 121(3):189-96. PubMed ID: 23030781
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.
Ostrowski SR; Katzenstein TL; Pedersen M; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2006 Jun; 63(6):478-86. PubMed ID: 16764702
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients.
Grunnet M; Christensen IJ; Lassen U; Jensen LH; Lydolph M; Lund IK; Thurison T; Høyer-Hansen G; Mau-Sørensen M
Clin Biochem; 2014 May; 47(7-8):599-604. PubMed ID: 24530340
[TBL] [Abstract][Full Text] [Related]
10. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
11. Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis.
Almasi CE; Christensen IJ; Høyer-Hansen G; Danø K; Pappot H; Dienemann H; Muley T
Lung Cancer; 2011 Dec; 74(3):510-5. PubMed ID: 21640427
[TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability.
Olson FJ; Thurison T; Ryndel M; Høyer-Hansen G; Fagerberg B
Clin Biochem; 2010 Jan; 43(1-2):124-30. PubMed ID: 19822140
[TBL] [Abstract][Full Text] [Related]
13. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
14. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
[TBL] [Abstract][Full Text] [Related]
15. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Almasi CE; Høyer-Hansen G; Christensen IJ; Danø K; Pappot H
Lung Cancer; 2005 Jun; 48(3):349-55. PubMed ID: 15893003
[TBL] [Abstract][Full Text] [Related]
19. A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.
Thurison T; Lomholt AF; Rasch MG; Lund IK; Nielsen HJ; Christensen IJ; Høyer-Hansen G
Clin Chem; 2010 Oct; 56(10):1636-40. PubMed ID: 20802096
[TBL] [Abstract][Full Text] [Related]
20. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
Lomholt AF; Høyer-Hansen G; Nielsen HJ; Christensen IJ
Br J Cancer; 2009 Sep; 101(6):992-7. PubMed ID: 19672256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]